InvestorsHub Logo
Followers 101
Posts 13436
Boards Moderated 2
Alias Born 01/23/2004

Re: Fido post# 7371

Wednesday, 05/11/2016 1:55:32 PM

Wednesday, May 11, 2016 1:55:32 PM

Post# of 12606
Promoting the product the wrong way.

I agree so it makes one wonder what they've been doing all these years.



Miller story is a great story, but when he speaks his story becomes the center of attention not the treatment.

On any one of Miller's interviews, have you ever seen a breakdown on the cost in money and time of Biocorrx treatment compared to traditional methods.

Have you seen any data on Biocorrx's specific treatment effectiveness in treating opiates addition rather than just stating in general naltrexone is being used in treating opiate dependency.

Hare you seen any data showing relapse rates of a individual who use the Biocorrx treatment vs traditional treatment.

Have you seen data comparing stoppage of cravings after a Biocorrx treatment vs traditional treatment.

These are the things that the company should be promoting not the Miller story.

Just because Biocorrx's treatment is not yet approved for opiate addition doesn't mean they couldn't done a few studies to show proof that their treatment was effective on opiate addiction.

They have a treatment, they proves it works, now the job of the company is to show why it is an economic alternative to the traditional treatments out there.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BICX News